Teleflex Incorporated has completed the acquisition of substantially all of BIOTRONIK's Vascular Intervention business, as announced earlier this year. The acquisition, finalized for a cash payment of €760 million with adjustments, significantly enhances Teleflex's global presence in the cath lab and expands its portfolio of interventional access products. This strategic move will establish Teleflex's footprint in the peripheral intervention market and support the company's innovation pipeline. The deal also provides an opportunity to advance the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold technology, with plans for a U.S. pivotal study.